博客

MSC Therapy for Atopic Dermatitis: Meta-Analysis of RCTs and Phase 2 Data Reveal

A 2026 meta-analysis pools 236 patients across 5 trials, and a 114-patient Phase 2 RCT shows MSC therapy achieves EASI-75 in 24% of severe AD patients. Exosome hydrogel delivery and batch consistency data now address the…

Oct 18, 2026

MSC Therapy for Parkinson’s Disease: What Randomized Trials and Comprehensive Reviews Reveal

Multiple 2026 clinical trials and reviews show mesenchymal stem cell therapy is safe and feasible for Parkinson's disease — but what do the actual data say about efficacy, dosing, and what comes next?

Oct 16, 2026

MSC Therapy for Pediatric Acute GvHD: From FDA Approval to Next-Generation Approaches

The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refra…

Oct 15, 2026

Can Stem Cell Therapy Help Children with Autism? What 2026 Research Shows

A double-blind RCT shows cord blood stem cells improved social cognition in children with autism. Here's what parents need to know about the latest research, safety data, and treatment process.

Oct 14, 2026

MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows

A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.

Oct 14, 2026

MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review

A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active…

Sep 23, 2026

MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal

The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce …

Sep 7, 2026

为什么你的干细胞在40岁后会减缓活动（以及科学界正在如何应对这一问题）

Research shows MSC activity drops 40% by age 50. Learn what changes inside aging cells and three emerging therapies showing real results in 2026 clinical trials.

Sep 4, 2026

MSC临床试验：ISCT都柏林会议揭示了半月板修复、线粒体移植和细胞来源方面的信息

A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.

Aug 28, 2026

脊髓损伤干细胞疗法：2026 年的研究将告诉我们脊髓损伤后 MSC 疗法的哪些信息

Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.

Aug 27, 2026

Stem Cell Therapy for Erectile Dysfunction: A Patient’s Guide to the 2026 Evidence

Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.

Aug 22, 2026

MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us

MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for r…

Aug 20, 2026

Page 1 of 6 — 68 posts